Key Findings
Improvements in healthcare infrastructure & the high prevalence of lifestyle diseases leading to increased surgeries and chronic disorders will be propelling market growth at a CAGR of 11.20% in the Asia Pacific region during the forecasting years of 2019-2027.

Market Insights
The growing confidence of physicians in the use of neurostimulation devices is also expected to enforce the market to progress. In addition, limited public awareness of neurostimulation devices, a shortage of skilled professionals, and the high cost of devices hinder market growth. China Neurostimulation device market is mainly driven by the constant rise in the population of the country which is impacting the prevalence of aging population along with the rising prevalence of dementia mainly in the semi-urban and rural provinces of the country.

Competitive Insights
Many companies are contending in the race to gain the maximum sum of profits. Some of them are Cogentix Medical Inc., St. Jude Medical Inc. (acquired by Abbott Laboratories), Aleva Neurotherapeutics SA, Boston Scientific Corporation, Helius Medical Technologies, The Magstim Company Limited, Cyberonics Inc., Neuronetics Inc., Depuy Synthes Companies, Ekso Bionics Holding Inc., Medtronic PLC, Dr. Langer Medical GmBH, Ectron Limited, Nevro Corp. and Hocoma AG.